To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Clinical trial NCT06194448 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06194448
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-21
- Primary completion
- 2026-07-07
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.